Protea Biosciences Group Inc. (fka PRGBQ)

[lucky, mydog]

another sec head scratcher.

https://www.sec.gov/litigation/opinions/2020/34-89599.pdf

[Renee]

PRGBQ BK PLAN effective. All shares cancelled.

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Renee]

PRGBQ SEC Suspension for severely delinquent Financials:

https://www.sec.gov/litigation/suspensions/2019/34-86759.pdf

Order:

https://www.sec.gov/litigation/suspensions/2019/34-86759-o.pdf

Admin. Proceeding:

https://www.sec.gov/litigation/admin/2019/34-86758.pdf

[Werbe]

Share Structure as of 5-30-18

Authorized Shares - 750,000,000

Outstanding Shares - 8,034,210

Restricted - 6,691,493

Unrestricted (float) - 1,342,717

Market Cap 3,214

52-Wk Range
0.0003 - 7.00

Protea Biosciences Group, Inc. is an molecular information company that has developed a revolutionary platform technology that enables the direct analysis, mapping and display of biologically active molecules in living cells and tissue samples. The technology platform offers new, unprecedented capabilities useful to the pharmaceutical, diagnostic, clinical research, agricultural and life science industries. “Molecular information” refers to the generation and bioinformatic processing of very large data sets, known as “big data,” obtained by applying the Company’s technology to identify and characterize the proteins, metabolites, lipids and other molecules which are the biologically active molecular products of all living cells and life forms.

Our technology is used to improve pharmaceutical development and life science research productivity and outcomes, and to extend and add value to other technologies that are used in research and development, such as three-dimensional tissue models, biomarker discovery, synthetic biologicals and mass spectrometry. In particular, the Company believes that its ability to rapidly provide comprehensive molecular image-based datasets addresses a universal need of the pharmaceutical, diagnostic and clinical research and life science industries.

The Company’s commercial development is centered on three lines of business:

Molecular information services – We believe that we are the commercial leader in providing multi-modal Mass Spectrometry Imaging (“MSI”), combining Laser Ablation Electrospray Ionization (“LAESI®”), Matrix Assisted Laser Desorption Ionization (“MALDI”) and optical microscopy. Our proprietary services enable the identification and quantitation of both small molecules (e.g., lipids and metabolites) and large molecules (e.g., proteins) and our services portfolio, inclusive of MSI, proteomics, metabolomics, lipidomics and bioinformatics is unique in the industry. Our clients include major pharmaceutical, chemical and biotechnology companies

LAESI® instrument platform – We offer our proprietary LAESI® DP-1000 instrument, software and bioanalytical consumables to corporate and academic research laboratories

Molecular diagnostics and clinical research – We apply our multi-modal MSI technologies and workflows in partnership with top-tier medical research institutions to co-develop new molecular diagnostic tests that the company believes can be used to improve the diagnosis and prognosis of cancer and provide requisite information useful in predicting the outcome of cancer treatment. Our current test development programs target the differential diagnosis and prognosis of malignant melanoma and the molecular profiling of subpopulations of cells in lung adenocarcinoma.

MORGANTOWN, W. Va, Aug. 8, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced today that it had entered into a Collaboration Research Agreement with the Vaccine and Immunotherapy Center (VIC), Division of the Massachusetts General Hospital (MGH) and Harvard Medical School. The goal is to co-develop a new diagnostic methodology that will provide cancer cell molecular profiles, including the distribution of drugs within cancer cells and molecular response indicators, to improve patient treatment and outcomes.

In April 2016, we entered into an exclusive license agreement for technology with Yale University related to the differential diagnosis of melanoma, specifically designated as a "Method of Differentiating Benign Melanocytic Nevi from Malignant Melanoma." The technology was co-invented by Dr. Rossitza Lazova, of the Department of Dermatology at Yale School of Medicine, and Dr. Erin Seeley, our Principal Investigator. Under the terms of the license agreement, we have been granted the exclusive worldwide rights to commercialize the technology.

On November 30, 2017, the Board of Directors (the “Board”) of the Company determined that it will be required to file a voluntary petition for reorganization under Chapter 11 (“Chapter 11”) of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court of West Virginia (the “Court”). The Company chose to seek bankruptcy protection after due consideration and upon the advice and recommendations of the Company’s chief restructuring officer, Compass Advisory Partners, LLC (the “CRO”).

As previously reported, the Company engaged the CRO on October 23, 2017 to evaluate and assess the Company’s financial outlook and to evaluate short-term options for new debt or equity financing. Following its review, the CRO recommended that the Company file for Chapter 11 bankruptcy protection. The Company intends to file the Chapter 11 Case on Friday, December 1, 2017. Following the filing, the Company will continue to operate its business at a reduced level as a “debtor-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court.

The Chief Restructuring Officer in charge here is very legit. Background is heavy in turning around real companies suffering from mismanagement. Info below.






http://www.proteabio.com/index.html
https://www.linkedin.com/company/protea-biosciences
https://www.facebook.com/proteabio
https://twitter.com/proteabio

[Renee]

PRGB: effective Dec. 5,2017 PRGB will change to PRGBQ, bankruptcy:

http://otce.finra.org/DLSymbolNameChanges

[Roland Rick Perry]

Hires Compass Advisory Partners, LLC,

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12342033

[Roland Rick Perry]

Studying this..

...as if this is the first day we ever looked at it.

8 million shares (after 50:1) equates to a $9.2 million market cap @ $1.15. Modest for any Company, most will agree, involved in cancer diagnostics.

Interesting side note. Steve Antoline a former director and the largest shareholder along with his wife Jamie, graciously donated $1 million to WVU for cancer research in August, which is walking distance from Protea's HQ's.

"..many great institutions and universities, including WVU, have come a long way with early detection methods, and in many cases, treatment that can help a cancer patient live a long and productive life. How great it would be if, with the help of research dollars, the cure for cancer was found at WVU." Steve Antoline.

https://wvutoday.wvu.edu/stories/2017/08/25/nicholas-county-couple-donates-1m-to-wvu-s-norma-mae-huggins-cancer-research-fund

Shareholder Roster (4/17)

https://www.otcmarkets.com/financialReportViewer?symbol=PRGBD&id=176960

"How great would it be if Protea's cancer detection technology jointly developed with Yale University, gets widely adopted and saves countless lives, by providing a quicker and more accurate prognostic/diagnostic melanoma cancer testing result and subsequent treatment decision?" Roland Perry :)

(In October 2015 scientists at Yale and Protea presented the results of their first clinical study at the 52nd Annual Meeting of the American Society of Dermatopathology (ASDP), held in San Francisco, CA. The sensitivity and specificity of the new method were shown to be 99%, and the test correctly classified all cases of malignant melanoma and benign melanocytic nevi. There are globally approximately three million skin biopsies annually to rule out the presence of melanoma; of these approximately 25% come back as “indeterminate” or “unknown”.)

https://www.europeanpharmaceuticalreview.com/article/40677/proteomic-mass-spectrometry-melanoma/

What we will be studying with great interest is the 'office level' experience of both the Physician and patient, after undergoing a biopsy which comes back as "don't know or not sure," if the patient actually has skin cancer or not.

Symbol goes back to PRGB November 13th.

[Renee]

PRGB: effective Oct. 16,2017 a one for 50 reverse split:

http://otce.finra.org/DLSymbolNameChanges

[HndtoHnd]

marketexclusive.com/protea-biosciences-group-inc-otcmktsprgb-files-an-8-k-regulation-fd-disclosure/2017/10/

[Roland Rick Perry]

Lucky Post #7.

Just had to grad that poll position. Studying.

[Rediculousd]

https://www.wsj.com/articles/the-breakdown-in-biomedical-research-1491576749

The Breakdown in Biomedical Research
Contaminated samples, faulty studies and inadequate training have created a crisis in laboratories and industry, slowing the quest for new treatments and cures

Protea Biosciences’s technology identifies molecules being produced by living cells, while untouched in ambient conditions. Huge solution to the contamination problem.

[brwtrpilot]

This company ,, check darpa and protea, also check out their website
frigging exciting tech.
Then look at the last 10k and pause.
sigh.

[Don_k1ng]

will there be any possible reverse split happening soon ??

[The Night Stalker]

lots of form 4

[QuickDraw007]

Watch for this stock to wake up in a few weeks!

[QuickDraw007]

First post ever!